Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 145,000 members, many of whom demonstrate better investing insight than published analysts do.
After Amylin Pharmaceuticals
Amylin and partner Eli Lilly
Diabetes is highly correlated with obesity, and a deal with Japanese company Takeda Pharmaceutical to develop Amylin's obesity compounds could give Amylin a huge boost in the obesity treatment market. Amylin pocketed $75 million up front, with the possibility for $1 billion or more for hitting certain milestones. CAPS members like the huge potential market for obesity drugs, as the World Health Organization estimates a continuing rise in the number of obese adults. Prescription drugs account for less than 1% of the massive weight-loss products market. Roche and Abbott Laboratories
Do you think Amylin Pharmaceuticals deserves its raised status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.
The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 51 points on average, take a free 30-day trial.